Guardant Health, Inc. GH revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Guardant Health, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $982M, 100.0% of the filed sum (+32.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$982M100.0%+32.9% yoy
Members sum to the consolidated $982M for this period.
- Oncology$684M69.6%+25.9% yoy
- Biopharma Data$210M21.4%+18.3% yoy
- Screening$79.7M8.1%+1456.0% yoy
- Licensing Other$8.56M0.9%-36.5% yoy
Members sum to the consolidated $982M for this period.
- United States$923M94.0%+32.4% yoy
- Outside the United States$58.7M6.0%+40.3% yoy
Members sum to the consolidated $982M for this period.
- Reportable Segment$335M100.0%+44.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.